Novartis to showcase transformative data in advanced prostate and early breast cancer at ESMO 2025
Novartis to showcase transformative data in advanced prostate and early breast cancer at ESMO 2025
arcticnovartis
- Key data from PSMAddition has been selected for a Presidential session; data to showcase the efficacy and safety of PluvictoTM plus standard of care (SoC) versus SoC alone in PSMA+ mHSPC
- NATALEE five-year analysis of Kisqali® to provide further long-term insights into risk of recurrence reduction in a broad EBC patient population